The effect of topical bevacizumab on corneal neovascularization

SW Kim, BJ Ha, EK Kim, H Tchah - Ophthalmology, 2008 - Elsevier
SW Kim, BJ Ha, EK Kim, H Tchah
Ophthalmology, 2008Elsevier
PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization
(NV) over a period of 3 months. DESIGN: Prospective, nonrandomized, masked
observational case series. PARTICIPANTS: Ten eyes of 7 patients with corneal NV.
METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic
evaluations included visual acuity, slit-lamp examination, and tonometry. MAIN OUTCOME
MEASURES: Corneal NV and changes in ophthalmic evaluations. RESULTS: Decreased …
PURPOSE
To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
DESIGN
Prospective, nonrandomized, masked observational case series.
PARTICIPANTS
Ten eyes of 7 patients with corneal NV.
METHODS
Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
MAIN OUTCOME MEASURES
Corneal NV and changes in ophthalmic evaluations.
RESULTS
Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
CONCLUSIONS
Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Elsevier